Author: Andrea Eberle

ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025 ANN ARBOR, Mich., Nov. 10, 2025 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver podium presentations at EYENOVATE and the FLORetina-ICOOR Congress 2025. This is…

ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic Solution ANN ARBOR, Mich., Oct. 28, 2025 – ONL…

ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings ANN ARBOR, Mich., Feb. 4, 2025 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will present clinical data and scientific research at the following first quarter meetings: Details of…